{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:12:05Z","timestamp":1764562325635,"version":"3.46.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jval.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:36:09Z","timestamp":1718825769000},"page":"1779-1788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Literature Review and Meta-Analysis of Primary Evidence Reporting Health-State Preference Values in Chronic Hepatitis B, C, and D"],"prefix":"10.1016","volume":"27","author":[{"given":"Ankita","family":"Kaushik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jo\u00e3o","family":"Janeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Arag\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2024.06.002_bib1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bpg.2008.11.002","article-title":"Chronic viral hepatitis as a public health issue in the world","volume":"22","author":"Lavanchy","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2024.06.002_bib3","first-page":"251","article-title":"Trends of the global hepatitis C disease burden: strategies to achieve elimination","volume":"54","author":"Brunner","year":"2021","journal-title":"J\u00a0Prev Med Public Health"},{"issue":"12","key":"10.1016\/j.jval.2024.06.002_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jvh.13371","article-title":"Disease burden of viral hepatitis A, B, C and E: a systematic analysis","volume":"27","author":"Liu","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib5","first-page":"90","article-title":"Prevalence and impact of hepatitis on the quality of life of patients","volume":"5","author":"Mittal","year":"2015","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"7","key":"10.1016\/j.jval.2024.06.002_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2012\/736452","article-title":"Health state utilities and quality of life in patients with hepatitis B","volume":"26","author":"Woo","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","article-title":"A\u00a0systematic review and meta-analysis of health utilities in patients with chronic hepatitis C","volume":"23","author":"Saeed","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21470-3","article-title":"Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan","volume":"12","author":"Sugimori","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jval.2024.06.002_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2020.0656","article-title":"Explaining health state utility assessment","volume":"323","author":"Chang","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11136-018-1992-3","article-title":"Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis","volume":"28","author":"Buchanan-Hughes","year":"2019","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40258-020-00600-w","article-title":"Systematic review of health state utility values used in European pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results","volume":"19","author":"Han","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis C from SF-36 scores","volume":"100","author":"Thein","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jval.2024.06.002_bib13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","article-title":"Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C","volume":"14","author":"Townsend","year":"2011","journal-title":"Value Health"},{"year":"2010","series-title":"NICE DSU Technical Support Document 9: The Identification, Review and Synthesis of Health State Utility Values from the Literature","author":"Papaioannou","key":"10.1016\/j.jval.2024.06.002_bib14"},{"issue":"9","key":"10.1016\/j.jval.2024.06.002_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40273-018-0670-1","article-title":"A\u00a0practical guide to conducting a systematic review and meta-analysis of health state utility values","volume":"36","author":"Petrou","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2024.06.002_bib16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2024.06.002_bib18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1111\/liv.14647","article-title":"Health related quality of life in chronic liver diseases","volume":"40","author":"Cortesi","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jval.2024.06.002_bib19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11136-019-02111-1","article-title":"Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population","volume":"28","author":"Juanbeltz","year":"2019","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1026473613487","article-title":"Physicians\u2019 assessments of the utility of health states associated with HIV and hepatitis B virus (HBV) infection","volume":"6","author":"Owens","year":"1997","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.jval.2024.06.002_bib21","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s11136-012-0318-0","article-title":"Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases","volume":"22","author":"Scalone","year":"2013","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jrsm.1319","article-title":"Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis","volume":"10","author":"Veroniki","year":"2019","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"A","key":"10.1016\/j.jval.2024.06.002_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A\u00a0comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"issue":"11","key":"10.1016\/j.jval.2024.06.002_bib27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"year":"1994","series-title":"The Handbook of Research Synthesis","author":"Cooper","key":"10.1016\/j.jval.2024.06.002_bib28"},{"issue":"10","key":"10.1016\/j.jval.2024.06.002_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-127-10-199711150-00001","article-title":"Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C","volume":"127","author":"Bennett","year":"1997","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2024.06.002_bib31","first-page":"14","article-title":"Revised SF-6D scoring programmes: a summary of improvements","volume":"40","author":"Brazier","year":"2008","journal-title":"PRO Newslett"},{"issue":"7","key":"10.1016\/j.jval.2024.06.002_bib32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/00365520902898135","article-title":"Health-related quality of life in patients with different stages of liver disease induced by hepatitis C","volume":"44","author":"Bj\u00f6rnsson","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-8278(03)00189-2","article-title":"Quality of life and cognitive function in hepatitis C at different stages of liver disease","volume":"39","author":"Cordoba","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jval.2013.04.008","article-title":"Italian population-based values of EQ-5D health states","volume":"16","author":"Scalone","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215596","article-title":"Quality of life in patients with chronic hepatitis C infection: severe comorbidities and disease perception matter more than liver-disease stage","volume":"14","author":"Cossais","year":"2019","journal-title":"PLoS One"},{"year":"2010","series-title":"Mesure de l\u2019Utilit\u00e9 Attach\u00e9e aux \u00c9tats de Sant\u00e9 : Valorisation de l\u2019Indes d\u2019Utilit\u00e9 EQ-5D et \u00c9volution de l\u2019\u00c9chelle actuelle en France","author":"Chevalier","key":"10.1016\/j.jval.2024.06.002_bib37"},{"issue":"6","key":"10.1016\/j.jval.2024.06.002_bib38","first-page":"1863","article-title":"Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal","volume":"22","author":"Dusheiko","year":"1995","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.510270132","article-title":"Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis","volume":"27","author":"Foster","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1478-3231.2008.01865.x","article-title":"Does cirrhosis affect quality of life in hepatitis C virus-infected patients?","volume":"29","author":"Hsu","year":"2009","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890109002092","article-title":"The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies","volume":"33","author":"Furlong","year":"2001","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1440-1746.2011.06813.x","article-title":"Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection","volume":"27","author":"Hsu","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"year":"2014","series-title":"Self-Reported Population Health: an International Perspective Based on EQ-5D","author":"Szende","key":"10.1016\/j.jval.2024.06.002_bib43"},{"issue":"10","key":"10.1016\/j.jval.2024.06.002_bib44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/0003-4819-127-10-199711150-00002","article-title":"Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C","volume":"127","author":"Kim","year":"1997","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/00365520500325952","article-title":"Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C","volume":"41","author":"Hollander","year":"2006","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jval.2024.06.002_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S1098-3015(10)67323-8","article-title":"Impact on quality of life of health states induced by chronic hepatitis B infection: estimates from uninfected and infected persons in the UK","volume":"8","author":"Ossa","year":"2005","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib47","article-title":"Health-related quality of life and utility values in chronic hepatitis C patients: a cross sectional study in France, the UK and Germany","volume":"62","author":"Pol","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jval.2024.06.002_bib48","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.936162","article-title":"Long-term effectiveness, safety, and patient-reported outcomes of self-administered subcutaneous hepatitis B immunoglobulin in liver post-transplant hepatitis B prophylaxis: a prospective non-interventional study","volume":"27","author":"Roche","year":"2022","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jval.2024.06.002_bib49","article-title":"Health utilities in chronic hepatitis c patients with decompensated cirrhosis or hepatocellular carcinoma","author":"Saeed","year":"2017","journal-title":"Toronto Health Economics and Technology Assessment Collaborative"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3138\/canlivj-2022-0009","article-title":"Disparities in health utilities among hepatitis C patients receiving care in different settings","volume":"6","author":"Saeed","year":"2023","journal-title":"Can Liver J"},{"issue":"9","key":"10.1016\/j.jval.2024.06.002_bib51","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031115","article-title":"Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies","volume":"7","author":"Bansback","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clinre.2014.10.013","article-title":"Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France","volume":"39","author":"Samp","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"21","key":"10.1016\/j.jval.2024.06.002_bib54","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.164.21.2377","article-title":"Health values of patients with chronic hepatitis C infection","volume":"164","author":"Sherman","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.jval.2024.06.002_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"issue":"9","key":"10.1016\/j.jval.2024.06.002_bib57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-122-9-199505010-00004","article-title":"Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B","volume":"122","author":"Wong","year":"1995","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.jval.2024.06.002_bib58","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.280.24.2088","article-title":"Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs","volume":"280","author":"Wong","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2024.06.002_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.15518","article-title":"Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings","volume":"43","author":"Wong","year":"2023","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1572-0241.2001.03537.x","article-title":"Assessment of utilities and health-related quality of life in patients with chronic liver disease","volume":"96","author":"Younossi","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/liv.12886","article-title":"The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study","volume":"36","author":"Younossi","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jval.2024.06.002_bib63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","article-title":"Sofosbuvir and Velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jval.2024.06.002_bib64","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/liv.14171","article-title":"Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: the impact of hepatitis B and C viral replication","volume":"39","author":"Younossi","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jval.2024.06.002_bib65","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2021.01.026","article-title":"Long-term patient-centered outcomes in cirrhotic patients with chronic hepatitis C after achieving sustained virologic response","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2024.06.002_bib66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5144\/0256-4947.2012.397","article-title":"Health-related quality of life of Saudi hepatitis B and C patients","volume":"32","author":"Abdo","year":"2012","journal-title":"Ann Saudi Med"},{"issue":"4","key":"10.1016\/j.jval.2024.06.002_bib67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.06.002_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/PROM.S226936","article-title":"Impact of stigma on people living with chronic hepatitis B","volume":"11","author":"Smith-Palmer","year":"2020","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"10.1016\/j.jval.2024.06.002_bib69","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","article-title":"A\u00a0comparison of the EQ-5D-3L and EQ-5D-5L","volume":"38","author":"Thompson","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2024.06.002_bib70","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40273-015-0310-y","article-title":"Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values?","volume":"33","author":"Peasgood","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib71","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.06.002_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s13104-019-4413-y","article-title":"Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease","volume":"12","author":"Briggs","year":"2019","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jval.2024.06.002_bib73","first-page":"293","article-title":"A\u00a0structured review of health utility measures and elicitation in advanced\/metastatic breast cancer","volume":"8","author":"Hao","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.jval.2024.06.002_bib74","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0272989X19841587","article-title":"Cultural values: can they explain differences in health utilities between countries?","volume":"39","author":"Roudijk","year":"2019","journal-title":"Med Decis Mak"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:46:42Z","timestamp":1764560802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1098301524027372"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Literature Review and Meta-Analysis of Primary Evidence Reporting Health-State Preference Values in Chronic Hepatitis B, C, and D","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}